Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Dow
Merck
Harvard Business School
Boehringer Ingelheim

Last Updated: January 27, 2023

Albireo Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Albireo
International Patents:119
US Patents:8
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Albireo

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 RX Yes No 10,981,952 See Plans and Pricing See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 RX Yes Yes 10,975,046 See Plans and Pricing Y See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 RX Yes No 9,694,018 See Plans and Pricing See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No See Plans and Pricing See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 RX Yes Yes 10,981,952 See Plans and Pricing See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes 10,975,046 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Albireo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Albireo BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 7,132,416 See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 7,132,416 See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 7,132,416 See Plans and Pricing
Albireo BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 7,132,416 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Albireo Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3400944 122021000075 Germany See Plans and Pricing PRODUCT NAME: ODEVIXIBAT, EINSCHLIESSLICH PHARMAZEUTISCH VERTRAEGLICHER SALZE UND SOLVATE DAVON, INSBESONDERE ODEVIXIBAT-HYDRAT; REGISTRATION NO/DATE: EU/1/21/1566 20210716
3400944 LUC00242 Luxembourg See Plans and Pricing PRODUCT NAME: ODEVIXIBAT ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BYLVAY); AUTHORISATION NUMBER AND DATE: EU/1/21/1566 20210719
3400944 CA 2022 00001 Denmark See Plans and Pricing PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719
3400944 48/2021 Austria See Plans and Pricing PRODUCT NAME: ODEVIXIBAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1566 (MITTEILUNG) 20210719
3400944 PA2021012 Lithuania See Plans and Pricing PRODUCT NAME: ODEVIKSIBATAS ; REGISTRATION NO/DATE: EU/1/21/1566 20210716
3400944 301157 Netherlands See Plans and Pricing PRODUCT NAME: ODEVIXIBAT OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1566 20210719
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
McKinsey
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.